Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesNatriuretic peptides as indicators of cardiac remodeling in hypertensive patients
Blood Pressure, 07/01/09
Magnusson M et al. – Findings show that natriuretic peptide levels increased with increasing number of markers of cardiac remodeling. N-terminal pro-atrial natriuretic peptide (Nt-ANP) and brain natriuretic peptide (BNP) are useful to discriminate between pts for cardiac remodeling and may be considered a screening tool to select pts eligible for further examination with echocardiography.
Methods- Study of the relationship between 3 different natriuretic peptides and left ventricular mass, function, and diameter and kidney function in hypertensive pts
- Subjects: 139 consecutive pts with moderate hypertension
- Analysis of Nt-BNP, BNP, and N-terminal pro-atrial natriuretic peptide (Nt-ANP)
- Echocardiography to assess cardiac remodeling
- Cystatin C to assess glomerular filtration
- Stratification by extent of cardiac remodeling: 1) no remodeling; 2) 1 of left ventricular hypertrophy, left ventricular dysfunction or left ventricular dilatation; 3) 2 of above and 4) all 3 parameters
- All peptides differed significantly between groups with a continuous stepwise increase from groups 1 through 4
- Receiver operating characteristic analysis showed equal diagnostic performances for detection of any cardiac abnormalities for Nt-BNP and BNP; both superior to Nt-ANP
- In multivariable linear regression analysis, all 3 indicators of cardiac remodeling independently correlated with Nt-BNP and BNP
- Only left ventricular diameter independently correlated with Nt-ANP
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Atherosclerosis, 10/07/09
Sponsor
Article Search
Sponsor